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Abstract
Background To describe disease parameters of patients with
Graves’ orbitopathy in a tertiary referral center in order to
plan health care resource allocations. To investigate whether
the clinical activity and/or the severity of the disease can be
used as a predictor of the duration of treatment.
Methods Retrospective, observational, non-comparative case
series. One hundred and seventeen charts of GO-patients,
randomly chosen out of a pool of 1600, referred to the
Orbital Unit of the University Medical Centre Utrecht
between 1 January 1992 and 1 January 2002, were analysed.
Relevant parameters, such as age, gender, race, disease
duration, smoking habits, concomitant diseases, previous
treatment, symptoms and signs, number and sort of inves-
tigations, severity and activity scores, number and sort of
treatments, treatment duration and outcome of treatment
were retrieved and analysed. Disease activity and severity at
entry were tested as possible predictors of disease duration
and extent of treatment.
Results Clinical profile at presentation; duration of the
disease; extent of treatment; predictors of disease duration
and of number of treatment interventions were the main
outcome measures. Three percent of patients had Only Signs,
but No Symptoms (OSNS), 61% had mild, 27% had
moderately severe and 9% had severe GO. Fifteen percent
had inactive disease at presentation, 65% had borderline
activity and only 20% had active orbitopathy. Sixty percent
complained about eyelid swelling and/or proptosis. The
average period of eye treatment was 2.5 years (range: 0–
110 months), during which patients were seen at an average
of 8 times. Twenty percent needed no treatment at all. Fifteen
percent were treated with nothing but lubricants and/or
prisms. Twenty-five percent were treated with immunosup-
pressive modalities. Fifty-six percent underwent one or more
surgical corrections. The Clinical Activity Score (CAS) was
found to be significantly related to the duration of the
treatment (p<0.001), to the number of visits (p<0.001), and
to the number of surgical interventions (p<0.001).
Conclusions The majority of GO patients referred to a
tertiary referral centre has no or borderline disease activity
and ‘mild’ orbitopathy, disfiguring eyelids and proptosis
being the most frequent complaints. The disease activity as
assessed with the CAS can be used to predict the duration
and extent of the treatment.
Keywords Graves’orbitopathy.Tertiaryreferral center.
Healthcare.Clinicalactivity.Severity.Predictor
Introduction
GO is part of a multi-system auto-immune disorder, including
Graves’ Thyroid Disease (GTD), Graves’ Dermopathy and
Graves’ Acropachy. [1, 2] The incidence of GTD in the
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or about 1200 female patients per year. [3]A p p r o x i m a t e l y ,
30–60% of them have ophthalmic/orbital involvement. [4]
GO often runs a course independently of GTD. GO is
described in terms of severity and activity. [5, 6]T h e
spontaneous course and the different stages of Graves’
orbitopathy have been described by Rundle. [7] Active and
more severe forms of GO, that do not improve spontane-
ously, are treated with immunosuppressive modalities. It is
common practice, however, to wait for the burnout stage of
the disease before rehabilitative surgery, such as proptosis
reduction, squint surgery and eyelid correction, is started.
GO is a mutilating and often disabling disease, considered
more difficult to carry than for instance diabetes mellitus [8].
Thus, there is a strong demand for treatment and the share of
GO-patients in an orbital center is considerable. Although
the efficacy and safety of individual immunosuppressive and
surgical interventions have been described extensively [9,
10], little has been published on the overall management of
GO [11]. We were, therefore, interested in the patient’s
clinical profile at presentation in a tertiary referral centre, the
duration of the disease and the number and outcome of
treatment interventions of a large cohort of GO-patients.
Furthermore, our goal was to define predictors for these
items in order to acquire evidence for streamlining a clinic
for GO-patients.
We applied two instruments: disease activity and disease
severity. Disease activity refers to the stage of the disease.
The stage can be assessed using the Clinical Activity Score,
which is based on the classical signs of inflammation, such
as pain, swelling, redness and impaired function. Ten items
can be scored, the sum being the CAS. [5, 6]
To assess disease severity we used a modified NO
SPECS classification.
Materials and methods
The files of all GO-patients, who’s family name started with
an A or a B, referred to the Orbital Unit of the University
Medical Centre Utrecht (UMCU) between 01/01/1992 and
01/01/2002, were retrospectively reviewed. Relevant data
such as age, gender, race, smoking habits, presence of
concomitant diseases and systemic disorders, history and
treatment of GTD were collected.
The included patients were divided into four groups of
disease severity. For this purpose, we applied a modified
NOSPECS classification [12]. We used a modified Zeiss-
Jena Hertel exophthalmometer, in which –for the sake of
the patient’s comfort- the footplate has been softened with
rubber rings. Compared to other Hertel meters, this
exophthalmometer shows lower readings. We therefore
tested this instrument and assessed the upper limits of
normal in another study. [13] Consecutively, we adapted the
NO SPECS classification in class III (Table 1).
Severity A Only signs (such as eyelid retraction), no
symptoms
Severity B NOSPECS class 2a or b, and/or 3a, and or 4a,
and/or 5a
Severity C NOSPECS class 2c, and/or 3b or 3c, and/or
4b, and/or 5b
Severity D NOSPECS class 4c, and/or 5c and/or 6a, or
6b, or 6c
To group our patients into classes of disease activity, we
considered patients with a Clinical Activity Score (CAS) of
less than 1 being ‘inactive’, patients with a CAS of 1 to 3
being borderline and those with a CAS of more than 3
being ‘active’.[ 6]
Statiscical analysis
All assembled data were entered into a specially designed
data base and checked by a medical analyst. The statistical
analysis was done with SPSS 14.0 software. To find
possible prediction models for the duration of treatment,
for the number of investigations, and the numbers of visits,
we used a stepwise regression analysis. We used the
forward conditional method with default selection criteria,
P<0.05 to enter and P>0.10 to remove. In order to correct
for their possible mutual influence, we used as independent
variables gender, age, complaints and symptoms during the
first and last visit, thyroid status, previous treatment and
duration of GO and GTD, and the categories for NOSPECS
and CAS.
Results
General characteristics and concomitant diseases
at first visit
See Table 2. Hundred and seventeen patients out of 1600
were included. All percentages in the text and tables are
valid percentages. Eighty percent of our patients were
female. The mean age of all patients was 48 years (range
Table 1 Modified NOSPECS class III. Using a modified Zeiss-Jena
exophthalmometer, we redefined class III (exophthalmos) as follows
3 o exophthalmos ≤ 17 mm for females and ≤ 20 mm for males
3 a exophthalmos 18 or 19 mm for females and 21 or 22 for males
3 b exophthalmos 20–22 mm for females and 23–25 mm for males
3 c exophthalmos ≥ 23 mm for females and ≥ 26 mm for males
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16. Both had mild, not active GO. Both were treated with
lubricants. The one of 16 years old underwent a unilateral
levator lengthening. Out of 117 patients, 112 were Cauca-
sian, 4 Asian, and 1 black. Sixty-four percent of patients
were cigarette smokers. Eight patients had concomitant
diabetes mellitus, 2 were suffering from a non-Hodgkin
lymphoma; 1 had vitiligo, 1 had thyroid dermopathy and 1
acropachy. The majority of our patients (56%) were referred
by an ophthalmologist outside our hospital.
Duration before referral, previous treatment
SeeTables3 and 4. At the time of their first visit to our clinic,
75% of the patients were suffering from GTD for more than
one year. Ninety percent had been treated with block and
replacement therapy (thyreostatics and thyroxin), 50% with
thyrostatics only, 34% with I
I31, and 12% had undergone
thyroidectomy. Fifty-eight percent of patients were clinically
and biochemically euthyroid, 20% were hyperthyroid, 12%
were hypothyroid, 1% had thyroiditis (in 9% the thyroid
status could not be retrieved in this material). As we could
regain, 49% had a history of GO shorter and 51% longer than
one year. Previous treatment of GO included lubricants in
30%, radiotherapy in 8%, oral prednisone in 15%, intrave-
nous prednisone in 3%. Fifteen patients out of 117 had
undergone some kind of surgery in connection to their GO; 7
of them had undergone an orbital decompression.
GO symptoms and sign
See Table 5.
Complaints
Being unhappy with their looks (eyelid swelling: 49%,
disfiguring proptosis: (44%), diplopia (45%), tearing
(45%), retrobulbar pain in rest or during eye movements
(40%), and photophobia (33%) were the most frequent
complaints, followed by blurred vision (25%) and feeling
of grittiness (19%).
Table 2 General patient characteristics at first visit to tertiary referral
centre
Age N
pts
Valid
%
Mean Min max
Male + female 49 14 86
Female 93 48 14 86
Male 24 51 24 73
Gender
Female 93 80
Male 24 20
Race
Asian 4 3
Black 1 1
Caucasian 112 96
Smoking
Yes 58 64
No 33 36
Concomitant diseases
DM 8 7
NHL 2 2
Dermopathy 1 0.9
Acropathy 1 0.9
Other eye diseases
Diabetic retinopathy 1 0.9
Cataract 4 3
Cataract 4 3
ARMD 1 0.9
Amblyopia 1 0.9
Referred by
General practioner 12 11
Ophthalmologist 63 56
Other hospital 9 8
Own hospital 21 19
Own initiative 4 3
Second opinion 4 3
Table 3 Thyroid parameters at first visit
N pts Valid %
Duration of GTD
<1 year 27 25
>1 year 81 75
Previous treatment
Thyrostatics 99 90
I131 38 34
thyroidectomy 13 12
Thyroid status
Euthyroid 66 58
Hyperthyroid 24 20
Hypothyroid 14 12
Thyroiditis 1 1
Unknown 10 9
Table 4 Eye parameters at first visit
N pts valid %
Duration of GO
<1 year 52 49
>1 year 55 51
Previous treatment
Lubricants 35 30
Oral Prednisone 17 15
I.V. Prednisone 3 3
Radiotherapy 9 8
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A best corrected visual acuity of less than 0.8 on the
Snellen chart, presumably due to GO, was found in 7% of
our patients. The average Hertel value of the worst eye,
using our modified Zeiss-Jena exophthalmometer was
17.8 mm (range:10–27, SD: 3.4 mm), the average for
females being 17.3, SD: 3.4 mm and for males 19.7, SD:
3.2 mm). Fifty-eight percent of the male and 57% of the
female patients had Hertel values above the upper limit of
normal in relationship to the modified Zeiss-Jena Hertel we
used. The average lid aperture was almost 12 mm (range: 3
to18, SD: 2.7 mm). Considering 10 mm the upper limit of
normal for the eyelid aperture in Caucasians, 76% of the
Caucasian patients had an abnormally enlarged palpebral
fissure. Fifty-two percent of our patients had normal eye
movements and no diplopia in any position of gaze, 31%
had diplopia in extremes of gaze and 17% had diplopia in
primary and reading position. Measurement of eye move-
ments in secondary positions of gaze with a modified
perimeter [14] showed an average of elevation of 25
0 (3–
42, SD:9.5
0), of depression of 54
0 (30–64, SD: 8.1
0)o f
abduction of 41
0 (18–50, SD:7.8
0) and of adduction of 45
0
(28–58, SD:5.6
0) (Numbers refer to the right eye; ductions
in the left eyes were comparable). Chemosis was present in
30%, caruncle swelling in 15%, corneal involvement in
10% of patients.
In 63 patients (54%) a CT-scan was made at the first
clinical examination. Nine of them (14%) had a normal
scan. Enlargement of the extraocular muscles was seen in
28%/29% (right eye/left eye), of retrobulbar fat in 13%/
11%, of the extraocular muscles and fat in 44%/44%.
Apical crowding was found in 3 patients.
Dysthyroid Optic Neuropathy (DON)/Additional
investigations
Additional tests for visual functions were only performed in
patients with suspected DON (n=27). Out of 117 patients, 9
(6 females, 3 males, mean age: 54.7) were considered to
have DON. Four had bilateral and 5 unilateral DON. The
visual acuity in the “DON-eye” varied from 0.4 - 0.63. All
but one had a CAS of > 3; 3 had apical crowding; all but
one had Hertel values of less than 21 mm. Colour vision,
visual fields and VEP did not always correlate to the
decrease of the visual acuity. All were treated with
prednisone (oral and/or I.V.) with or without retrobulbar
irradiation and followed by orbital decompression in 2. At
the end of treatment, the CAS was ≤ 1 in all. Full recovery
of visual acuity was seen in 9 DON-eyes.
Treatment
Twenty percent underwent no treatment at all. Fifteen
percent were treated with nothing but lubricants and/or
prisms. Twenty-nine patients (25%) were treated with (a
combination of) immunosuppressive treatment. Of those,
13 patients were treated with prednisone orally, 10 with
prednisone intravenous, 15 with orbital irradiation, and 1
patient with cyclosporine (9 received some kind of a
combination of these). Radiotherapy was applied in patients
with active disease and severe motility impairment.
More than half of all patients (56%) required surgical
interventions. Twenty-five patients (21%) underwent orbital
decompression (9% by a lid/conjunctiva – 2 wall and 12%
by coronal – 3 wall approach). Strabismus was corrected in
25 patients (21%). Eyelid lengthening (upper and/or lower,
with and without implants) was done in 44 patients (38%).
Blepharoplasty (upper and lower lids) was performed in 35
patients (32%) (Table 6).
Table 5 Ophthalmic findings in 117 GO patients at first visit to
tertiary referral centre
N Valid percent
Retrobulbar pain 47 40
Tearing 53 45
Photophobia 38 33
Grittiness 22 19
Double vision 53 45
Blurred vision 29 25
Unhappy with eyelids 57 49
Unhappy with proptosis 52 44
Lid aperture > 10 mm 80 76
Eyelid swelling 75 65
Eyelid redness 12 10
Chemosis 34 30
Conjunctival redness 29 25
Canuncle swelling 17 15
Superior Limbic keratitis 1 1
Corneal stippling 12 10
Normal VA 98 84
Reduced VA due to GO 8/6 7/5
Reduced VA due to other causes 10/12 9/10
Hertel > ULN, males 52 58
Hertel > ULN, females 13 57
No diplopia 58 52
Diplopia in extremes of gaze 35 31
Diplopia in all directions 19 17
Enlarged muscles on CT 16/18 25/29
Increased fat volume 8 /11 13/11
Increase muscle + fat 28/28 45/45
Apical crowding 2/3 3/5
No abnormalities 9/7 14/11
When two numbers are given per item, the first refers to the right and
the second to the left eye. When one number per item is given, this
number refers either to the patient or to the eyes, in which the findings
in OD and OS were exactly similar. OD= Right eye, OS= Left Eye
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Using our modified NOSPECS classification, 3% of the
included patients had type A GO (only signs, no symp-
toms), 61% had type B (mild GO), 27% had type C
(moderately severe), 9% had type D (severe GO). Eight
percent had DON at their first visit. Among the patients
with a history of GO of more than one year, 9 patients had
inactive, 39 borderline activity and 7 active orbitopathy.
Among those with a GO history of less than one year, these
numbers were 8, 29 and 15 respectively.
Independently from the treatment, the severity of GO
increased in 5%, did not change in 52% and improved in
43%. (Table 7). ‘Inactive GO’ (CAS<1) was assessed in
15%, ‘borderline activity’ (CAS 1–3) in 65% and ‘active’
(CAS>3) in 20%. Seventy-eight percent had OSNS, mild
or moderate orbitopathy with a CAS of less than 4. Of all
patients, less then 1 percent of patients deteriorated, 35%
remained stable and 64% improved in terms of activity
(Table 8). Of those, who were managed without immuno-
suppressive or surgical treatment (N=40), 1 inactive patient
(3%) developed borderline activity; 1 patient (3%) with
OSNS developed mild GO and three (8%) with mild GO
developed moderately severe GO.
Duration of the treatment
The average duration of treatment was 28 months (range 0–
110, SD:25.4 months). An “average patient” visited our
hospital 8 times (range: 1–37, SD:6.6) and underwent 0.5
(range 0–3, SD:0.9) operations under general and 0.8
(range 0–4, SD:1.0) corrections in local anaesthesia.
Prediction
Regressionanalysisshowedasignificantrelationshipbetween
the CAS value and the duration of the treatment (p<0.001),
between the CAS value and the number of visits (p<0.001)
and between the CAS value and the number of surgical
interventions (p<0.001). No significant correlation could be
found between these items and the severity of the disease at
first visit as expressed in the Total Eye Score (TES) [15].
Comparison of subgroups
For the study, we defined smokers as those who were still
smoking at the time of referral or those who had stopped
smoking less than 12 months ago. All others were
considered non-smokers. Comparing the subgroup of
smokers with non-smokers, we found a significant differ-
ence in the severity at the moment of referral. Smokers had
more proptosis (p=0.04) and more motility impairment (p=
0.03). No significant differences between the two sub-
groups could be assessed as for the total number of visits to
our clinic or for the duration of the disease or for the
number of interventions.
Comparing the subsets of patients who had had major
interventions (such as immunosuppressive treatment or
surgery) before referral to our centre with those who had had
no other treatment than lubricants, we found no significant
differences in severity, outcome and disease duration.
Comparing the subgroups of patients who had I
131 –
treatment before or during their eye treatment in our
Table 6 Treatment in our centre
Treatment UMCU N pts valid %
No treatment 23 20
Lubricants 63 54
Oral Prednisone 13 11
IV Prednisone 10 9
Cyclosporine 1 1
Radiotherapy 15 13
Any surgery 65 56
Decompression 25 21
Strabismus surgery 25 21
Eyelid lengthening upper/lower 44 38
Blepharoplasty upper/lower 35 32
Table 7 Cross-table showing severity of GO (worst eye) according to
the modified NOSPECS classification at first and last visits (numbers
of patients)
NOSPECS last visit Total
NOSPECS 1st visit A B C D
A310 0 4
B1 74 9 40 7 0
C 5 18 7 1 33
D054 11 0
25 73 15 2 115
Deteriorations in red. Improvement in blue. So, four patients had class
A at first visit. Of those 4, at the last visit, one had class B, one class C
and zero class D.
Table 8 Cross-table showing activity of GO (worst eye) according to
the CAS classification at first and last visits (numbers of patients)
CAS, last visit Total
CAS 1st
visit
Inactive Borderline Active
Inactive 16 1 0 17
Borderline 50 23 0 73
Active 16 7 0 23
82 31 0 113
Deterioration in red. Improvement in blue.
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131
we found no significant differences in severity and outcome.
Discussion
This is a retrospective study, in which we use valid
percentages because not all data of each included patient
were available. For instance, the CAS at first visit had not
been described in 4 out of 117 patients and the NO SPECS
classification could not be retrieved in 2 patients. The
referral pattern to our unit may not be identical for other
orbital centres in the world. These limitations have to be
taken into account. Our findings confirm earlier studies
regarding the female preponderance in GO, the age
distribution, and presenting symptoms. [1, 2] In accordance
with previous studies, almost 60% of our patients had
exophthalmometry values above the upper limit of normal.
Considering 10 mm the upper limit of normal for the eyelid
aperture in Caucasians, 76% of all patients had an
abnormally enlarged palpebral fissure. Thus, proptosis
together with eyelid retraction is the most common
presentation of GO at our unit.
At the time of referral to our centre, 51% of the patients
had orbitopathy for more than 12 months and in 75% the
diagnosis of dysthyroidism had been made more than one
year before. In spite of these considerable delays, 20% of
the referred patients were still hyper- and 12% hypothyroid,
indicating the difficulty to achieve euthyroidism in some
Graves patients. Rendering a patient euthyroid, however, is
of utmost importance as it may be beneficial to the ocular
status as well. [16] The prevalence of active disease (CAS>
3) among patients with a GO duration of less than one year
was more than twice as much as among those with a GO
duration of more than one year (p=0.055). However, 13%
of the last group still had active GO, indicating that disease
duration and disease activity are not interchangeable.
Ninety percent of our patients had been treated with
thyrostatics and only 34% with radioactive iodine. These
percentages are more or less similar with other European
centres [14], but differ from those in North-America [2],
reflecting the popularity of I
131 in the treatment of
hyperthyroidism in the latter countries. The prevalence of
smokers in our study group (64%) is clearly higher than in
other studies (54%) [2] and (40%) [17]. Although smoking
is considered a risk factor for the development of severe
GO [18], in our series we could not find a significant
correlation between smoking and severity (as expressed in
the NOSPECS- classification) or activity of GO (p=0,71
and p=0,52). However, smokers were found to be more
proptosed and to have more motility impairment than non-
smokers at the time of referral. Moreover, out of 9 patients
with DON, 6 were smokers and out of 22 patients with a
CAS>3, 16 were current smokers. A diagnosis of DON is
sometimes difficult to make, as the condition is not well
defined. We considered 9 patients (8%) to have DON. It
was striking that all but one of these patients had high
CAS-values. Some kind of surgery was eventually carried
out in 56% of our patients. This number is high and may
reflect the long history of rehabilitative orbital decompres-
sion in the Netherlands.
In general, the clinical presentation of GO varies from
minimal eyelid swelling and retraction to disfiguring
proptosis, severe motility restriction and reduced vision due
to a corneal ulcer or optic nerve compression. However, the
GO patients seen at our tertiary referral center, basically fall
into two categories. The patient most frequently seen was a
middle aged woman with a history of GTD of more than one
year and with non-active eye disease consisting of eyelid
alterations and proptosis and sometimes limitation of motion
in the extremes of gaze (Category I). The orbitopathy they
have we call “mild” or moderately severe, because vision is
normal and there is no significant diplopia. However, these
patients themselves do not consider their disease “mild”,a s
they may be handicapped by tearing and irritation and last
but not least by the social implications of their changed
looks. We believe a CT scan in this group is only required
when the diagnosis cannot be made on the clinical picture
alone or when orbital decompression is planned. The chance
to deteriorate in this subgroup is small. In our patients the
chance to deteriorate for those who didn’t receive treatment
other than local measures was 11 percent and the deteriora-
tion was very modest. These patients can thus safely
prescribed local measures and return after three months.
Then, when the clinical findings are stable, they return to
their referents or are planned for eyelid surgery (lengthening
with or without blepharoplasty in local anaesthesia) or for
orbital decompression followed by accessory surgery (squint
and/or eyelid surgery), if required.
The second category, approximately one-third of patients
(36%) have more severe forms of GO. More than half of
these patients have active disease (e.g. CAS>3). Older men
are relatively frequent in this group. Their symptoms vary
from severe proptosis to motility restriction causing diplopia
and to reduced vision. To follow their disease development,
repeated ophthalmic, orthoptic and even CT scans are
required. Depending on the severity and the activity of the
disease,treatmentoptionsare immunosuppressive therapyor
acute orbital decompression. In our clinic, we reserve orbital
decompressions for those, who do not respond to immuno-
suppressive treatment. In case of suspected optical nerve
involvement, additional testes are performed (colour vision,
visual field, VEP). If the CAS is low or has become low after
immunosuppressive treatment (needed in approximately 1
out of 4 GO patients), these patients are rehabilitated
surgically just as category I patients.
1320 Graefes Arch Clin Exp Ophthalmol (2008) 246:1315–1321As patients with active orbitopathy, in contrast to
patients with inactive disease, require not only rehabilitative
surgery, but previous immunosuppressive treatment as well,
activity of the disease at entry is the most important
predictor of the disease duration, the number of visits and
of interventions, as demonstrated by our findings.
This study allows us to estimate the logistic consequen-
ces and treatment planning of a GO-patient at a tertiary
referral centre. Twenty-five percent of patients needs RT or
immune-suppressive treatment; 20 percent needs orbital
decompression, the same percentage squint surgery and 40
percent eyelid surgery. An average of 8 controls is
necessary. The total duration of the eye treatment is
2.5 years. With these data, patients can be informed about
the number and kind of interventions they can expect and
the duration of their social and functional disability.
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